Drug Trial Radar · NCT06198712
A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease
Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
95
Planned (sponsor's estimate)
Start
Jan 12, 2023
Primary completion
Feb 23, 2028
Study completion Aug 8, 2029
Sponsor
- Lead sponsor
- Forma Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Novo Nordisk A/S. This study is currently undergoing a sponsor transition from Forma Therapeutics, Inc. to Novo Nordisk A/S.
- First posted
- Jan 10, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 months, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the pharmacokinetics and safety of etavopivat in paediatric participants with sickle cell disease (SCD). Participants will receive etavopivat and will be enrolled in a staggered manner, starting with the oldest age group and followed sequentially by younger cohorts after review of pharmacokinetic and safety data from the preceding cohort. All participants will undergo a 24-week primary treatment period followed by a 72-week extension treatment period to further evaluate long-term safety and pharmacokinetics of etavopivat. The total duration of the study will be approximately 96 weeks.
Conditions
- Sickle Cell Disease
Interventions
EtavopivatDrug
Participants will receive oral tablets or granules of etavopivat once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Single-dose: maximum plasma concentration (Cmax)Time frame: During the 24-week primary treatment period
- Single-dose: area under the plasma concentration time curve from dosing (time 0) to time t ((AUC)0-t)Time frame: During the 24-week primary treatment period
- Single-dose: area under the plasma concentration time curve from zero to time infinity (AUC0-inf)Time frame: During the 24-week primary treatment period
- Steady-state maximum plasma concentration (Cmax,ss)Time frame: During the 24-week primary treatment period
- Steady-state area under the concentration time curve over the dosing interval (AUCtau,ss)Time frame: During the 24-week primary treatment period
- Steady-state average plasma concentration (Cavg,ss)Time frame: During the 24-week primary treatment period
- Steady-state minimum plasma concentration (Cmin,ss)Time frame: During the 24-week primary treatment period
- Incidence of adverse events (AEs), serious adverse events (SAEs), and AEs related to etavopivatTime frame: During the 24-week primary treatment period
- Number of premature discontinuationsTime frame: During the 24-week primary treatment period
- Number of dose interruptionsTime frame: During the 24-week primary treatment period
- Number of dose reductionsTime frame: During the 24-week primary treatment period
Locations
18 sites in 7 countries. Site status is shown where the registry gives one.
The Hospital for Sick Children
Toronto, Ontario, Canada · Completed
HCL-HOPITAL LYON SUD_Institut d'Hématologie et d'Oncologie Pédiatrique (IHOPe)
Lyon, France · Not yet recruiting
APHP - Centre de Référence des Syndromes
Paris, France · Not yet recruiting
Centre Hospitalier Universitaire de Rouen-Hopital Charles Nicolle
Roeun, France · Not yet recruiting
KEMRI-Walter-Reed Kericho
Kericho, Kenya · Recruiting
Kombewa Clinical Research Centre
Kisumu, Kenya · Recruiting
Ahero Clinical Trials Unit
Kisumu, Kenya · Recruiting
KEMRI CRDR Siaya Clinical Research Annex, Country Referral Hospital
Siaya, Siaya County, Kenya · Recruiting
American University of Beirut Medical center
Beirut, Lebanon · Recruiting
Hospital Nini
Tripoli, Lebanon · Recruiting
Lagos University Teaching Hospital, Lagos
Lagos, Nigeria · Recruiting
Aminu Kano Teaching Hospital (AKTH)
Tarauni, Nigeria · Recruiting
University of Nigeria Teaching Hospital (UNTH)
Ituku-Ozalla, Enugu State, Nigeria · Recruiting
Hacettepe University pediatric hematology
Ankara, Turkey (Türkiye) · Completed
Acıbadem Adana Hastanesi
Seyhan, Turkey (Türkiye) · Completed
Guys and St Thomas NHS Foundation Trust / Evelina Childrens Hospital
London, United Kingdom · Recruiting
King's College Hospital - Alex Mowat Research Hub
London, United Kingdom · Recruiting
Manchester Royal Infirmary_1
Manchester, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.